AAAAAA

   
Results: 1-14 |
Results: 14
Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: An algorithm for percutaneous management
Authors: Dippel, EJ Kereiakes, DJ Tramuta, DA Broderick, TM Shimshak, TM Roth, EM Hattemer, CR Runyon, JP Whang, DD Schneider, JF Abbottsmith, CW
Citation: Ej. Dippel et al., Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: An algorithm for percutaneous management, CATHET C IN, 52(3), 2001, pp. 279-286
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effectsof dalteparin or unfractionated heparin in combination with abciximab
Authors: Furman, MI Kereiakes, DJ Krueger, LA Mueller, MN Pieper, K Broderick, TM Schneider, JF Howard, WL Fox, ML Barnard, MR Frelinger, AL Michelson, AD
Citation: Mi. Furman et al., Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effectsof dalteparin or unfractionated heparin in combination with abciximab, AM HEART J, 142(5), 2001, pp. 790-798
Dalteparin in combination with abciximab during percutaneous coronary intervention
Authors: Kereiakes, DJ Kleiman, NS Fry, E Mwawasi, G Lengerich, R Maresh, K Burkert, ML Aquilina, JW DeLoof, M Broderick, TM Shimshak, TM
Citation: Dj. Kereiakes et al., Dalteparin in combination with abciximab during percutaneous coronary intervention, AM HEART J, 141(3), 2001, pp. 348-352
Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: A new look at an old problem
Authors: Kereiakes, DJ Broderick, TM Abbottsmith, C Shimshak, TM
Citation: Dj. Kereiakes et al., Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: A new look at an old problem, J INVAS CAR, 12(2), 2000, pp. 95-98
Accelerating the return to work (RTW) chances of coronary heart disease (CHD) patients: part 1 - development and validation of a training programme
Authors: Mital, A Shrey, DE Govindaraju, M Broderick, TM Colon-Brown, K Gustin, BW
Citation: A. Mital et al., Accelerating the return to work (RTW) chances of coronary heart disease (CHD) patients: part 1 - development and validation of a training programme, DISABIL REH, 22(13-14), 2000, pp. 604-620
High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists
Authors: Kereiakes, DJ Broderick, TM Roth, EM Whang, D Mueller, M Lacock, P Anderson, LC Howard, W Blanck, C Schneider, J Abbottsmith, CA
Citation: Dj. Kereiakes et al., High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists, J THROMB TH, 9(2), 2000, pp. 149-155
Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials)
Authors: Kereiakes, D Linnemeier, TJ Baim, DS Kuntz, R O'Shaughnessy, C Hermiller, J Fink, S Lansky, A Nishimura, N Broderick, TM Popma, J
Citation: D. Kereiakes et al., Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials), AM J CARD, 86(3), 2000, pp. 336
Therapeutic adjuncts for immediate transfer to the catheterization laboratory in patients with acute coronary syndromes
Authors: Kereiakes, DJ Young, J Broderick, TM Shimshak, TM Abbottsmith, CW
Citation: Dj. Kereiakes et al., Therapeutic adjuncts for immediate transfer to the catheterization laboratory in patients with acute coronary syndromes, AM J CARD, 86(12B), 2000, pp. 10M-17M
IIb's are not IIb's
Authors: Kereiakes, DJ Runyon, JP Broderick, TM Shimshak, TM
Citation: Dj. Kereiakes et al., IIb's are not IIb's, AM J CARD, 85(8A), 2000, pp. 23C-31C
Abciximab provides cost-effective survival advantage in high-volume interventional practice
Authors: Kereiakes, DJ Obenchain, RL Barber, BL Smith, A McDonald, M Broderick, TM Runyon, JP Shimshak, TM Schneider, JF Hattemer, CR Roth, EM Whang, DD Cocks, D Abbottsmith, CW
Citation: Dj. Kereiakes et al., Abciximab provides cost-effective survival advantage in high-volume interventional practice, AM HEART J, 140(4), 2000, pp. 603-610
Efficacy of abciximab induced platelet blockade using a rapid point of care assay
Authors: Kereiakes, DJ Mueller, M Howard, W Lacock, P Anderson, LC Broderick, TM Roth, EM Whang, DD Abbottsmith, CW
Citation: Dj. Kereiakes et al., Efficacy of abciximab induced platelet blockade using a rapid point of care assay, J THROMB TH, 7(3), 1999, pp. 265-275
Job-simulated phase II cardiac rehabilitation training program: Part A. A comparison with conventional phase II cardiac rehabilitation training program
Authors: Mital, A Shrey, DE Govindaraju, M Broderick, TM Colon-Brown, K Gustin, BW
Citation: A. Mital et al., Job-simulated phase II cardiac rehabilitation training program: Part A. A comparison with conventional phase II cardiac rehabilitation training program, INT J IND E, 24(5), 1999, pp. 515-529
Job-simulated phase II cardiac rehabilitation training: Part B. Effects oftraining
Authors: Mital, A Shrey, DE Govindaraju, M Broderick, TM Colon-Brown, K Gustin, BW
Citation: A. Mital et al., Job-simulated phase II cardiac rehabilitation training: Part B. Effects oftraining, INT J IND E, 24(5), 1999, pp. 531-543
Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
Authors: Kereiakes, DJ Broderick, TM Roth, EM Whang, D Shimshak, T Runyon, JP Hattemer, C Schneider, J Lacock, P Mueller, M Abbottsmith, CW
Citation: Dj. Kereiakes et al., Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention, AM J CARD, 84(4), 1999, pp. 391-395
Risultati: 1-14 |